Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01310205 · ClinicalTrials.gov registry record
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
A clinical trial of Chronic Hepatitis C, sponsored by SciClone Pharmaceuticals.
- Completed
- Registry status
- 12
- Enrollment target
- 4
- Study locations
NCT01310205: Completed study of Chronic Hepatitis C, sponsored by SciClone Pharmaceuticals.
NCT01310205 is a study of Chronic Hepatitis C that has completed, run by SciClone Pharmaceuticals. The registered enrollment target is 12 participants, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01310205, a study of Chronic Hepatitis C, has completed, sponsored by SciClone Pharmaceuticals.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an extension of ongoing study SCI-SCV-HCV-P2-001 in which subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV.
Conditions Studied
Interventions
- DRUG SCV-07
Study Locations (4)
California
- AGMG Clinical Research - Anaheim
Kentucky
- Univ of Louisville Med/Dental Complex - Louisville
Ohio
- University of Cincinnati Medical Center - Cincinnati
Washington
- Walter Reed Army Medical Center - Washington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-03 |
What the finished NCT01310205 record still lists
NCT01310205 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which SCV-07 is the first listed.
NCT01310205 reports a single indexed study location in California, Kentucky, Ohio.
Frequently Asked Questions
What is clinical trial NCT01310205 about?
NCT01310205 is a clinical study titled "Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV". This is an extension of ongoing study SCI-SCV-HCV-P2-001 in which subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV.
What is the current status of trial NCT01310205?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2010-08. Estimated completion is 2012-03.
What conditions does trial NCT01310205 study?
This clinical trial studies the following conditions: Chronic Hepatitis C.
What interventions are being tested in trial NCT01310205?
The interventions under investigation include: SCV-07 (DRUG).
Who is sponsoring clinical trial NCT01310205?
This trial is sponsored by SciClone Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01310205 being conducted?
This trial has 4 study locations across California, Kentucky, Ohio, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01310205's enrollment target sits among peer trials
12 16th of 16 the lowest of 16 other Chronic Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
COMPLETED · Phase 1
-
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
COMPLETED · Phase 3
-
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
COMPLETED · Phase 3
-
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
COMPLETED · Phase 2
-
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
COMPLETED · Phase 2
-
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia